Trial Profile
A Multicenter, Randomized, Controlled Phase 2 Study: Efficacy and Safety of I-131-1095 Radiotherapy in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Who Are 18F-DCFPyL Prostate-specific Membrane Antigen (PSMA)-Avid, Chemotherapy-naive, and Progressed on Abiraterone
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Nov 2023
Price :
$35
*
At a glance
- Drugs LNTH 1095 (Primary) ; Enzalutamide
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms ARROW
- Sponsors Progenics Pharmaceuticals
- 20 Nov 2023 Planned End Date changed from 1 Jun 2024 to 24 Sep 2024.
- 08 Jun 2022 Status changed from recruiting to active, no longer recruiting.
- 24 Sep 2021 Planned number of patients changed from 175 to 120.